Arcellx (NASDAQ:ACLX) Insider Sells $10,243,230.72 in Stock

Arcellx, Inc. (NASDAQ:ACLX) insider Rami Elghandour sold 89,916 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the sale, the insider directly owned 276,051 shares in the company, valued at approximately $31,447,729.92. The trade was a 24.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Arcellx Stock Performance

Arcellx stock opened at $113.79 on Monday. The stock has a 50-day simple moving average of $71.81 and a 200 day simple moving average of $76.28. The stock has a market capitalization of $6.65 billion, a P/E ratio of -28.95 and a beta of 0.22. Arcellx, Inc. has a 52 week low of $47.86 and a 52 week high of $114.26.

Analyst Ratings Changes

A number of research firms recently weighed in on ACLX. Guggenheim cut Arcellx from a “buy” rating to a “neutral” rating and dropped their price target for the company from $120.00 to $115.00 in a research note on Wednesday. UBS Group downgraded shares of Arcellx from a “buy” rating to a “neutral” rating and upped their price objective for the company from $100.00 to $115.00 in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcellx in a research note on Wednesday, January 21st. Evercore set a $115.00 price target on shares of Arcellx in a research note on Monday, February 23rd. Finally, Robert W. Baird reissued a “neutral” rating and issued a $115.00 price target (up from $106.00) on shares of Arcellx in a report on Monday, February 23rd. One investment analyst has rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $111.87.

Hedge Funds Weigh In On Arcellx

A number of hedge funds have recently bought and sold shares of ACLX. Schroder Investment Management Group acquired a new stake in shares of Arcellx in the second quarter valued at approximately $3,951,000. Monaco Asset Management SAM bought a new position in Arcellx during the 3rd quarter worth $6,452,000. Pathway Capital Management LP acquired a new position in Arcellx in the 3rd quarter valued at $4,191,000. Y Intercept Hong Kong Ltd acquired a new position in Arcellx in the 3rd quarter valued at $1,273,000. Finally, American Century Companies Inc. lifted its position in shares of Arcellx by 694.3% during the 2nd quarter. American Century Companies Inc. now owns 431,466 shares of the company’s stock valued at $28,412,000 after acquiring an additional 377,145 shares during the period. 96.03% of the stock is owned by institutional investors.

Arcellx News Summary

Here are the key news stories impacting Arcellx this week:

• Neutral Sentiment: Reported short-interest data shows zero shares and a 0.0 days-to-cover figure for late February; this looks like a data or reporting anomaly rather than a meaningful change in market positioning — monitor for corrected filings or confirmations from exchanges.
• Neutral Sentiment: HC Wainwright published an FY2030 earnings forecast for Arcellx; long-range model updates can influence valuation assumptions but are less likely to move the stock immediately than near-term operational news. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
• Neutral Sentiment: Market commentary pieces (example: “Is It Too Late To Consider Arcellx…”) are evaluating the recent run-up and valuation; these are background reads that may sway retail interest but do not constitute new company fundamentals. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
• Negative Sentiment: Insider selling: Director Rami Elghandour sold 89,916 shares at ~$113.92 (≈$10.24M), cutting his stake by ~24.6%. Large insider sales at current levels can weigh on sentiment, especially after a recent price run. SEC Filing
• Negative Sentiment: Quarterly results: ACLX reported EPS of ($1.01), matching consensus, but revenue was $1.65M vs. expectations of $13.4M — a sizable revenue shortfall that highlights execution or timing risk and likely increases near-term volatility and downside pressure.
• Negative Sentiment: Analyst actions: UBS downgraded the stock, and both Robert W. Baird and Canaccord Genuity moved ACLX to “Hold” — multiple downward analyst moves reduce buy-side momentum and can trigger short-term selling. UBS downgrades Arcellx (ACLX) Cut to Hold at Robert W. Baird Cut to Hold at Canaccord Genuity Group

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.